XTX Topco Ltd Buys Shares of 52,344 Anavex Life Sciences Corp. (NASDAQ:AVXL)

XTX Topco Ltd purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 52,344 shares of the biotechnology company’s stock, valued at approximately $562,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AVXL. Barclays PLC boosted its stake in Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after buying an additional 64,101 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Anavex Life Sciences during the 4th quarter worth approximately $243,000. Wellington Management Group LLP acquired a new stake in Anavex Life Sciences in the 4th quarter valued at approximately $1,704,000. Heartland Advisors Inc. purchased a new stake in Anavex Life Sciences in the fourth quarter valued at approximately $1,674,000. Finally, Virtu Financial LLC purchased a new position in shares of Anavex Life Sciences during the fourth quarter worth $967,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Trading Up 1.2 %

Anavex Life Sciences stock opened at $8.95 on Friday. The firm has a market capitalization of $761.32 million, a P/E ratio of -16.27 and a beta of 0.80. The stock’s fifty day simple moving average is $8.72 and its 200-day simple moving average is $8.64. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Sell-side analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AVXL shares. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Monday, April 7th. D. Boral Capital reiterated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday, April 7th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.